Quantcast

Novartis Reports European Commission Approval Of Kymriah CAR-T Cell Therapy


Shutterstock photo


(RTTNews.com) - Novartis ( NVS ) announced the European Commission has approved Kymriah for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia that is refractory, in relapse post-transplant or in second or later relapse; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.

Kymriah is a one-time treatment that uses a patient's own T cells to fight cancer, and the only chimeric antigen receptor T cell (CAR-T) therapy to receive regulatory approval in the EU for these two distinct B-cell malignancies.

Novartis expects to launch initially in the pediatric acute lymphoblastic leukemia indication, as the company continues to ramp up capacity.


Read the original article on RTTNews (http://www.rttnews.com/2929520/novartis-reports-european-commission-approval-of-kymriah-car-t-cell-therapy.aspx)


For comments and feedback: contact editorial@rttnews.com




This article appears in: World Markets , Stocks , Economy , Commodities
Referenced Symbols: NVS



More from RTT News

Subscribe






See All RTT news











Research Brokers before you trade

Want to trade FX?